INmune Bio, Inc. to Report First Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, May 3

3 years ago

Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, April 24, 2023…

ICU Medical Announces Time of First Quarter 2023 Earnings Conference Call

3 years ago

SAN CLEMENTE, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and…

Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer

3 years ago

IRVINE, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet…

Shockwave Medical Announces Details for Conference Call Discussing First Quarter 2023 Results and Participation in Upcoming Investor Conference

3 years ago

SANTA CLARA, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of…

Smart for Life to Participate in MicroCap Rodeo’s ‘Lassoing the Big Apple’ Conference May 16-17

3 years ago

Conference Represents Initiation of Enhanced Outreach Activities to Increase AwarenessMIAMI, April 24, 2023 (GLOBE NEWSWIRE) -- Smart for Life, Inc.…

Panbela to Host First Quarter 2023 Earnings Conference Call on May 4, 2023

3 years ago

MINNEAPOLIS, April 24, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the…

Pharma Two B to Present Additional Positive Results from P2B001 Phase 3 Trial at 2023 American Academy of Neurology Annual Meeting

3 years ago

Results showed P2B001, a once-daily fixed-dose combination of low dose pramipexole and low dose rasagiline, showed comparable efficacy to marketed…

Qualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing

3 years ago

CARLSBAD, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life…

Vaxcyte Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

3 years ago

SAN CARLOS, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity…